MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical Evidence

    Core Laboratory

    An independent, centralized laboratory that performs standardized, blinded analysis of imaging or physiologic data from multiple trial sites to produce consistent endpoint adjudication.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026

    Definition

    A core laboratory (core lab) is an independent facility contracted in a clinical trial to perform centralized, standardized acquisition, processing, and interpretation of study data, most commonly imaging such as angiography, echocardiography, or CT/MRI, but also ECG, pulmonary function, or other physiologic measurements. By analyzing all subjects' data using a single set of trained readers and a common protocol, a core lab reduces the inter-site and inter-reader variability that would occur if each investigational site's local personnel interpreted their own images, and it allows readers to remain blinded to treatment assignment and clinical outcome, which protects against assessment bias in device trials where blinding of the intervention itself may not be feasible.
    What the regulation says
    FDA’s November 2013 guidance, Design Considerations for Pivotal Clinical Investigations for Medical Devices, recommends trial-design measures that minimize bias, including blinded outcome assessment where appropriate. For MedTech trials using imaging or physiologic endpoints, centralized, blinded review can support consistent endpoint measurement when investigators or participants cannot be blinded. This guidance is nonbinding and should not be described as imposing a universal requirement for a core laboratory, a standalone core lab charter, or strict organizational independence from the sponsor. Reader training, standardized methods, and procedures for resolving disagreements help implement these bias-control principles. In the EU, Regulation (EU) 2017/745, adopted on 5 April 2017 and generally applicable from 26 May 2021, establishes clinical-investigation requirements through Article 62 and Annex XV. Article 62 requires investigations to protect participants and produce scientifically valid, reliable, and robust clinical data. Annex XV addresses the clinical investigation plan, including methods to minimize bias and the approach to assessing clinical performance and safety. These provisions do not universally mandate a core lab. Where one is used, documenting its responsibilities, reading procedures, blinding arrangements, and data-handling methods helps demonstrate how the investigation meets those requirements.

    What this means in practice

    Core labs are particularly important for medical device pivotal trials submitted to FDA under a PMA or de novo pathway, where the primary effectiveness endpoint is often an imaging-based or physiologic measurement, such as minimal lumen diameter in a coronary stent trial or ejection fraction in a structural heart trial. FDA's investigational device exemption and PMA review teams frequently expect core lab charters that pre-specify reader qualifications, adjudication procedures for reader disagreement, and independence from the sponsor to be documented in the study protocol and included in the submission.

    Examples

    • A coronary stent trial uses a core lab to consistently measure minimal lumen diameter from angiographic images across all participating sites, ensuring standardized data for primary endpoint analysis.
    • For a heart valve trial, a core lab analyzes all echocardiograms to assess ejection fraction and valve function, reducing variability that might arise from different local site interpretations.
    • A neurovascular device study employs a core lab to centralize the reading of CT scans, allowing expert neuroradiologists to uniformly evaluate lesion volumes and treatment efficacy across multiple hospitals.
    Common pitfalls
    • •Allowing site-level image interpretation to substitute for core lab adjudication of a primary endpoint, which introduces variability that reviewers may flag as a study limitation.
    • •Failing to pre-specify the adjudication process for discordant reads between two core lab readers, leading to post hoc, and therefore less credible, tie-breaking decisions.
    • •Underestimating the image and data transfer logistics, including de-identification and file format standardization, needed to keep a core lab blinded and operationally efficient across many sites.

    Frequently asked questions

    A core lab standardizes measurement technique and keeps readers blinded to treatment and outcome, reducing variability and bias that would otherwise weaken confidence in an imaging-based or physiologic primary endpoint.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 3
    Link health: 2 verified 1 unchecked· last checked 2026-06-20
    1. 1
      FDA Guidance, Clinical Investigator Responsibilities
      Tier 2 Verified
      FDAfda.gov
    2. 2
      FDA Guidance, Design Considerations for Pivotal Clinical Investigations for Medical Devices
      Tier 2 Unchecked
      FDAfda.gov
    3. 3
      FDA - Clinical Trials and Human Subject Protection
      Tier 2 Verified
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.